Table 3.
FICI values obtained from CFD in combination with PIP-TAZ, FOS, CAZ-AVI, IMI-REL, MER-VAB and AMP-SULB against CR strains included in this study. FICI values in synergistic range are reported in bold.
| Isolates | CFD/PIP-TAZ 1 | CFD/FOS 2 | CFD/CAZ-AVI 3 | CFD/IMI-REL 4 | CFD/MER-VAB 5 | CFD/AMP-SULB 6 |
|---|---|---|---|---|---|---|
| CRE 1 | 1.25 | 0.50 | 0.38 | 0.63 | 0.63 | 0.88 |
| CRE 2 | 1.00 | 0.86 | 0.83 | 1.00 | 0.75 | 1.47 |
| CR-Ab 1 | 2.00 | 0.44 | 2.00 | 2.00 | 2.00 | 2.00 |
| CR-Ab 2 | 1.50 | 1.01 | 1.75 | 2.00 | 2.00 | 1.50 |
| CR-Pa 1 | 1.00 | 1.00 | 0.50 | 0.63 | 1.25 | 0.50 |
| CR-Pa 2 | 2 | 1.75 | 2 | 0.63 | 1.26 | 2 |
1 CFD/PIP-TAZ, cefiderocol/piperacillin-tazobactam; 2 CFD/FOS, cefiderocol/fosfomycin; 3 CFD/CAZ-AVI, cefiderocol/ceftadidime-avibactam; 4 CFD/IMI-REL, cefiderocol/imipenem-relebactam; 5 CFD/MER-VAB, cefiderocol/meropenem-vaborbactam; 6 CFD/AMP-SULB, cefiderocol/ampicillin-sulbactam.